Clinical Trial Update: CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CB-839 with everolimus vs placebo with everolimus in clear cell renal cell carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• CB-839 (telaglenastat)
• Everolimus (everolimus)

Snippet

Sponsor: Calithera Biosciences, Inc | Conditions: Clear Cell Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2022-09-15